Using tiny ultrasound agents to diagnose and treat type 1 diabetes
Submicron ultrasound contrast agents as diagnostic agents and therapeutic vehicles in type 1 diabetes
This study is looking at new ways to help people at risk of type 1 diabetes by using tiny ultrasound agents to deliver treatments directly to the pancreas, aiming to stop the disease before it starts.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10873718 on NIH RePORTER |
What this research studies
This research focuses on developing new diagnostic and therapeutic methods for type 1 diabetes (T1D) by utilizing submicron ultrasound contrast agents. These agents aim to target and deliver treatments specifically to the pancreatic islets, where the autoimmune destruction of insulin-producing beta cells occurs. The study explores the use of peptide therapeutics that can promote immune tolerance and prevent diabetes onset, particularly during the presymptomatic phase of T1D. By optimizing the delivery of these agents, the research seeks to improve the effectiveness of treatments for patients at risk of developing T1D.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for type 1 diabetes, particularly those with a family history or early signs of autoimmune activity against insulin-producing cells.
Not a fit: Patients who have already been diagnosed with type 1 diabetes and are experiencing significant symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective early interventions for individuals at risk of developing type 1 diabetes, potentially preventing the disease altogether.
How similar studies have performed: While there have been promising results in preclinical studies using peptide therapeutics, this specific approach with ultrasound contrast agents is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Ciccaglione, Mark — University of Colorado Denver
- Study coordinator: Ciccaglione, Mark
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.